Can a drug for one bone disease help another? a Rare-Disorder trial puts it to the test
Disease control
Completed
This early-phase trial is testing whether burosumab, a drug already approved for X-linked hypophosphatemia (XLH), can safely raise phosphate levels in a single patient with cutaneous skeletal hypophosphatemia syndrome (CSHS). Both conditions involve abnormally high FGF23 activity…
Phase: EARLY_PHASE1 • Sponsor: Laura Tosi • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC